Last reviewed · How we verify
Placebo + Prolonged Imaginal Exposure — Competitive Intelligence Brief
phase 3
Psychiatry/Mental Health
Small molecule
Live · refreshed every 30 min
Target snapshot
Placebo + Prolonged Imaginal Exposure (Placebo + Prolonged Imaginal Exposure) — Weill Medical College of Cornell University. Placebo combined with prolonged imaginal exposure therapy leverages psychological habituation to trauma memories through repeated, extended mental reliving of traumatic events.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Placebo + Prolonged Imaginal Exposure TARGET | Placebo + Prolonged Imaginal Exposure | Weill Medical College of Cornell University | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Placebo + Prolonged Imaginal Exposure CI watch — RSS
- Placebo + Prolonged Imaginal Exposure CI watch — Atom
- Placebo + Prolonged Imaginal Exposure CI watch — JSON
- Placebo + Prolonged Imaginal Exposure alone — RSS
Cite this brief
Drug Landscape (2026). Placebo + Prolonged Imaginal Exposure — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-prolonged-imaginal-exposure. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab